Tokio Marine Asset Management Co. Ltd. trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 7.6% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 131,069 shares of the biopharmaceutical company’s stock after selling 10,842 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Pfizer were worth $4,679,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Valueinvest Asset Management S.A. increased its holdings in Pfizer by 3.1% in the 1st quarter. Valueinvest Asset Management S.A. now owns 3,825,100 shares of the biopharmaceutical company’s stock valued at $130,857,000 after acquiring an additional 115,200 shares during the last quarter. AQR Capital Management LLC increased its holdings in Pfizer by 5.4% in the 1st quarter. AQR Capital Management LLC now owns 10,872,207 shares of the biopharmaceutical company’s stock valued at $371,939,000 after acquiring an additional 559,289 shares during the last quarter. Oakview Capital Management L.P. increased its holdings in Pfizer by 9.9% in the 1st quarter. Oakview Capital Management L.P. now owns 609,293 shares of the biopharmaceutical company’s stock valued at $20,844,000 after acquiring an additional 54,883 shares during the last quarter. Southeast Asset Advisors Inc. increased its holdings in Pfizer by 2.8% in the 1st quarter. Southeast Asset Advisors Inc. now owns 38,782 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 1,053 shares during the last quarter. Finally, National Asset Management Inc. increased its holdings in Pfizer by 0.7% in the 1st quarter. National Asset Management Inc. now owns 114,247 shares of the biopharmaceutical company’s stock valued at $3,911,000 after acquiring an additional 782 shares during the last quarter. Hedge funds and other institutional investors own 69.74% of the company’s stock.
In related news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Insiders have sold a total of 29,450 shares of company stock valued at $1,065,220 in the last quarter. 0.06% of the stock is currently owned by company insiders.
Pfizer Inc. (NYSE PFE) opened at $36.45 on Tuesday. Pfizer Inc. has a 52 week low of $30.90 and a 52 week high of $37.35. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market cap of $217,270.00, a PE ratio of 22.36, a P/E/G ratio of 2.46 and a beta of 1.01.
Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the previous year, the company earned $0.61 EPS. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current year.
Pfizer announced that its Board of Directors has authorized a share repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, February 2nd will be issued a dividend of $0.34 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a yield of 3.73%. Pfizer’s dividend payout ratio (DPR) is presently 78.53%.
ILLEGAL ACTIVITY NOTICE: “Pfizer Inc. (PFE) Stake Lowered by Tokio Marine Asset Management Co. Ltd.” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/09/pfizer-inc-pfe-stake-lowered-by-tokio-marine-asset-management-co-ltd.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.